Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Tirzepatide, a dual GLP-1/GIP receptor agonist approved as Mounjaro for diabetes and Zepbound for weight management, has demonstrated superior efficacy compared to semaglutide in head-to-head trials (SURPASS-2 for diabetes
Adems, es recomendable evitar los alimentos ultraprocesados y el exceso de azcares, ya que pueden afectar la eficacia del medicamento
Cost considerations Insurance coverage and out-of-pocket expenses vary between the two options
The company had already achieved significant success with Tirzepatide, which activates two receptors (GIP and GLP-1)
US$ 29.00
US$ 22.03
US$ 20.47
